combines Lantus with Adlyxin (Lxyumia outside the US). Both 2-in-1 once daily injectables aim to help patients not controlling their type 2 diabetes with insulin alone or with a GLP-1 alone.

Sanofi's follow-up product to its insulin blockbuster Lantus has been approved in Europe. Toujeo (insulin glargine [rDNA origin]) has been approved for the treatment of type 1 and type 2 diabetes ...

Objective—Insulin glargine (Lantus) is an extended-action insulin analog with greater stability and duration of action than regular human insulin. The long duration of action and decreased ...

While the QWINT-2 study compared efsitora with Novo’s Tresiba in T2D patients using basal insulin for the first time, the QWINT-4 study evaluated efsitora against Sanofi’s Lantus in T2D ...